IRON CHELATION THERAPY IMPROVES HAEMATOLOGICAL RESPONSE IN HIGH-RISK MYELODYSPLASTIC PATIENTS TREATED WITH AZACITIDINE

被引：0
|
作者：
Villa, M. R. [1 ]
Gagliardi, A. [1 ]
Della Cioppa, P. [1 ]
Esposito, M. [1 ]
Lucania, A. [1 ]
Izzo, G. Nitrato [1 ]
Improta, S. [1 ]
Mastrullo, L. [1 ]
机构：
[1] ASL Napoli 1 Ctr, UOC Ematol PO San Gennaro, Naples, Italy
来源：
HAEMATOLOGICA | 2016年 / 101卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P111
引用
收藏
页码：S120 / S121
页数：2
相关论文
共 50 条
  • [31] Efficacy and safety of a 5-day regimen of azacitidine for patients with high-risk myelodysplastic syndromes
    Fujimaki, Katsumichi
    Miyashita, Kazuho
    Kawasaki, Rika
    Tomita, Naoto
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2016, 97 (03) : 228 - 231
  • [32] Efficacy and Safety of a 5-Day Regimen of Azacitidine for Patients with High-Risk Myelodysplastic Syndromes
    Fujimaki, Katsumichi
    Miyashita, Kazuho
    Kawasaki, Rika
    Tomita, Naoto
    Ishigatsubo, Yoshiaki
    BLOOD, 2014, 124 (21)
  • [33] Guidelines on iron chelation therapy in patients with myelodysplastic syndrome and transfusion iron overload
    Gattermann, N.
    LEUKEMIA RESEARCH, 2007, 31 : S15 - S16
  • [34] Iron overload and chelation therapy in patients with low-risk myelodysplastic syndromes with transfusion requirements
    Angel F. Remacha
    Beatriz Arrizabalaga
    Consuelo Del Cañizo
    Guillermo Sanz
    Ana Villegas
    Annals of Hematology, 2010, 89 : 147 - 154
  • [35] Iron overload and chelation therapy in patients with low-risk myelodysplastic syndromes with transfusion requirements
    Remacha, Angel F.
    Arrizabalaga, Beatriz
    Del Canizo, Consuelo
    Sanz, Guillermo
    Villegas, Ana
    ANNALS OF HEMATOLOGY, 2010, 89 (02) : 147 - 154
  • [36] Guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload
    Gattermann, Norbert
    LEUKEMIA RESEARCH, 2007, 31 : S10 - S15
  • [37] Adequate iron chelation therapy for at least six months improves survival in transfusion-dependent patients with lower risk myelodysplastic syndromes
    Delforge, Michel
    Selleslag, Dominik
    Beguin, Yves
    Triffet, Agnes
    Mineur, Philippe
    Theunissen, Koen
    Graux, Carlos
    Trullemans, Fabienne
    Boulet, Dominique
    Van Eygen, Koen
    Noens, Lucien
    Van Steenweghen, Steven
    Lemmens, Jan
    Pierre, Pascal
    D'hondt, Randal
    Ferrant, Augustin
    Deeren, Dries
    Van De Velde, Ann
    Wynendaele, Wim
    Andre, Marc
    De Bock, Robrecht
    Efira, Andre
    Breems, Dimitri
    Deweweire, Anne
    Geldhof, Kurt
    Pluymers, Wim
    Harrington, Amanda
    MacDonald, Karen
    Abraham, Ivo
    Ravoet, Christophe
    LEUKEMIA RESEARCH, 2014, 38 (05) : 557 - 563
  • [38] Evolution of iron overload in patients with low-risk myelodysplastic syndrome: iron chelation therapy and organ complications
    Ángel F. Remacha
    Beatriz Arrizabalaga
    Ana Villegas
    María Soledad Durán
    Lourdes Hermosín
    Raquel de Paz
    Marta Garcia
    Maria Diez Campelo
    Guillermo Sanz
    Annals of Hematology, 2015, 94 : 779 - 787
  • [39] Evolution of iron overload in patients with low-risk myelodysplastic syndrome: iron chelation therapy and organ complications
    Remacha, Angel F.
    Arrizabalaga, Beatriz
    Villegas, Ana
    Soledad Duran, Maria
    Hermosin, Lourdes
    de Paz, Raquel
    Garcia, Marta
    Diez Campelo, Maria
    Sanz, Guillermo
    ANNALS OF HEMATOLOGY, 2015, 94 (05) : 779 - 787
  • [40] Identification of predictive factors for overall survival at baseline and during azacitidine treatment in high-risk myelodysplastic syndrome patients treated in the clinical practice
    Scalzulli, Emilia
    Molica, Matteo
    Fegatelli, Danilo Alunni
    Colafigli, Gioia
    Rizzo, Lorenzo
    Mancini, Marco
    Efficace, Fabio
    Latagliata, Roberto
    Foa, Robin
    Breccia, Massimo
    ANNALS OF HEMATOLOGY, 2019, 98 (08) : 1919 - 1925
12345